MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/80/0.1/20.12.24

MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/80/0.1/20.12.24 Share Price

DE000MB3F254

Market Closed - Börse Stuttgart 12:12:09 27/06/2024 am IST
0.52 ^EUR	-1.89%

Current month	+10.64%
1 month	-1.89%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/80/0.1/20.12.24

Latest news about ASTRAZENECA PLC

Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology	30/11	PR
New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy	14/23/14	PR
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research	27/22/27	PR
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer	14/22/14	PR

More news

Quotes 5-day view

Date	Price	Change
26/24/26	0.52	-1.89%
25/24/25	0.53	+1.92%
24/24/24	0.52	+1.96%
21/24/21	0.51	+8.51%
20/24/20	0.47	+2.17%

Delayed Quote Börse Stuttgart

Last update June 27, 2024 at 12:12 am IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	Morgan Stanley
WKN	MB3F25
ISIN	DE000MB3F254
Date issued	08/02/2023
Strike	80 $
Maturity	20/12/2024 (177 Days)
Parity	10 : 1
Emission price	0.43 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.85 €
Lowest since issue	0.048 €
Delta	0.53x
Omega	7.764
Premium	8.01x
Gearing	14.52x
Moneyness	0.9889
Difference Strike	0.92 $
Difference Strike %	+1.15%
Spread	0.02 €
Spread %	3.85%
Theoretical value	0.5100
Implied Volatility	24.60 %
Total Loss Probability	52.71 %
Intrinsic value	0.000000
Present value	0.5100
Break even	85.45 €
Theta	-0.01x
Vega	0.02x
Rho	0.02x

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: AstraZeneca PLC

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

158.5 USD

Average target price

174.4 USD

Spread / Average Target

+10.04%

Consensus